ASSESSMENT OF CARDIOVASCULAR AND RENAL OUTCOMES FOLLOWING DAPAGLIFLOZIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE. A-JMRHS [Internet]. 2026 Jun. 30 [cited 2026 Jul. 1];4(2):1398-403. Available from: https://www.ajmrhs.com/journal/article/view/617